OTCM
RDGL
Market cap22mUSD
Oct 08, Last price
0.05USD
1D
4.76%
1Q
-43.97%
IPO
-87.87%
Name
Vivos Inc
Chart & performance
P/E
—
P/S
331.42
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.23%
Rev. gr., 5y
57.75%
Revenues
68k
+144.25%
Net income
-3m
L+5.36%
CFO
-2m
L+22.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals. Additionally, the company provides IsoPet, a specific treatment for solid tumors found in animals. Established in 1994, Vivos Inc. is based in Richland, Washington. It previously operated under the name Advanced Medical Isotope Corporation before rebranding to Vivos Inc. in December 2017.
Key people
Carlton M. Cadwell
Chairman of the Board, Secretary · since 2016
Michael K. Korenko
President, Chief Executive Officer, Director · since 2017
Chairman of the Board, Chief Executive Officer
Michael Pollack
Interim Chief Financial Officer · since 2018
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
1021 North Kellogg Street
Kennewick, WA 99336
US
Kennewick, WA 99336
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||